Skip to main content
. 2010 Aug 2;120(9):3234–3241. doi: 10.1172/JCI42672

Figure 1. Treg analysis for patients and healthy volunteers.

Figure 1

Patient blood was analyzed prevaccination and at week 12 (3 weeks following the fourth and final vaccination) by flow cytometry staining for CD4+CD25+ and intracellular FoxP3 to determine percentage of Tregs. (A) The percentage of CD4+CD25+FoxP3+ cells and the (B) number of CD4+CD25+FoxP3+ cells per μl whole blood are represented for each patient by a square for cohort 1, triangle for cohort 2, and circle for cohort 3 (maximal tolerated dose [MTD]) at prevaccination week 0 and postvaccination week 12. (A) The percentage of CD4+CD25+FoxP3+ cells of normal donors (ND) was determined and analyzed using the same methods and is presented as a comparison (diamonds). The mean (bar) is also represented for ND, before vaccination, and after vaccination. Statistical significance is noted by Student’s t test between percentage of Tregs of normal donors and cancer patients in the study (P = 0.03). The differences in the percentage of Tregs before and after vaccination are not statistically significant for any of the vaccine doses (P > 0.2).